Noopur Raje, MD, Shares Myeloma Research Updates From ASH 2023

Dr. Raje discusses with Blood Cancers Today two “big” presentations in myeloma at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

“At this year’s ASH, I think the big thing is we are finally going to say that the standard of care for newly diagnosed patients is going to be four-drug regimens,” Dr. Raje said. “There’s going to be two big presentations. One is the plenary session [on the] IsKia trial, which is combining carfilzomib, lenalidomide, dexamethasone, and isatuximab.”

She also spoke about the Perseus trial, a late-breaking ASH abstract.

“These trials, at least with respect to response and [measurable residual disease] negativity, have shown that the four-drug regimen is better and, at least with the Perseus trial, we’ll see there is longer-term follow-up. There [are] data in the abstract as well where we have about 85% of patients remaining progression free at four years,” she said.